v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

UNCHARACTERISTIC RANGE OF FUNDUS FLUORESCEIN ANGIOGRAPHY CHARACTER IN MIDDLE SEROUS CHORIORETINOPATHY

AUTHORS:

Dr Muhammad Waleed Khalid, Dr Zaeema Kanwal, Dr Sundas Asghar

ABSTRACT:

Background: An eye illness that originates visual mutilation, frequently temporarily, typically in single eye called central serous chorioretinopathy. A indistinct or dreary mark in the middle illustration field is frequent when the retina is disconnected. Fundus Fluorescein Angiography can reveal abnormal blood vessels or damage to the lining underneath the retina. Objective: This study aimed at determination of atypical and unusual patterns of this disease on Fundus Fluorescein Angiography (FFA). Design of study: This study was descriptive. Patients & Methods: All those patients who were diagnosed with central serous chorioretinopathy and undergone FFA, were selected for study. Atypical patterns of this disease were analyzed. When no proper result was found with FFA, optical coherence tomography was done in order to get the proper conclusions. Results: There were 23 patients included in this study. Abnormal FFA features were shown in 12 patients. These features were: various ink spots in one eye and both eyes, pigment epithelial detachment along with CSR but demonstration of pigment epithelial detachment only on FFA, growth of blood vessels originating from choroid along with CSR where these vessels demonstrate on FFA only and no leakage from CSR is shown on FFA, smoke stalk and ink spot in same eye. Conclusion: Diagnostic problems can arise due to abnormal features of CSR. These features must be analyzed carefully by the doctors. Such cases should be treated by keeping in view, their association with eye diseases. Key words: FFA, OCT Atypical CSR.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.